Management of Acute Severe Colitis in the Era of Biologicals and Small Molecules

Christine Verdon; Talat Bessissow; Peter L Lakatos

doi:10.3390/jcm8122169

Management of Acute Severe Colitis in the Era of Biologicals and Small Molecules

J Clin Med. 2019 Dec 8;8(12):2169. doi: 10.3390/jcm8122169.

Authors

Christine Verdon^{1

2}, Talat Bessissow¹, Peter L Lakatos^{1

3}

Affiliations

¹ Division of Gastroenterology, McGill University Health Centre, Montreal, QC H3G 1A4, Canada.
² Department of Gastroenterology, Campbelltown Hospital, Sydney, NSW 2560, Australia.
³ 1st Department of Medicine, Semmelweis University, Budapest H1083, Hungary.

Abstract

Acute severe ulcerative colitis (ASUC) is a medical emergency which occurs in about 20%-30% of patients with ulcerative colitis during their lifetime, and does carry a mortality risk of 1%. The management of inflammatory bowel diseases has evolved with changes in objective patient monitoring, as well as the availability of new treatment options with the development of new biological and small molecules; however, data is limited regarding their use in the context of ASUC. This review aims to discuss the emerging data regarding biologicals and small molecules therapies in the context of ASUC.

Keywords: acute severe ulcerative colitis; corticosteroids; cyclosporine; infliximab; surgical management; tacrolimus.

Publication types

Review